Aethlon Medical, Inc. (AEMD)
| Market Cap | 4.49M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.56M |
| Shares Out | 2.58M |
| EPS (ttm) | -8.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 134,794 |
| Open | 1.750 |
| Previous Close | 1.770 |
| Day's Range | 1.658 - 1.835 |
| 52-Week Range | 1.658 - 8.440 |
| Beta | 1.88 |
| Analysts | Strong Buy |
| Price Target | 56.00 (+302.3%) |
| Earnings Date | Aug 13, 2025 |
About AEMD
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device for cancer and life-threatening viral infections and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for AEMD stock is "Strong Buy" and the 12-month stock price forecast is $56.0.
News
Aethlon Medical Treats Second Patient in Australian Hemopurifier® Cancer Trial
Second Patient in first cohort enrolled and treated at the Royal North Shore Hospital/University of Sydney Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies S...
Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes
Poster Presentation Reviews the Hemopurifier ® Affinity Resin's A bility to Bind Extracellular Vesicles in Long COVID Samples SAN DIEGO , June 9, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AE...
Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma
Results Reinforce the Current Australian Oncology Clinical Trial and Support Investigation of the Hemopurifier Across Multiple Indications SAN DIEGO , May 14, 2025 /PRNewswire/ -- Aethlon Medical, Inc...
Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal
Preclinical Data Suggests Expanded Therapeutic Potential of the Hemopurifier® Beyond Virology and Oncology Results Support Further Evaluation of the Hemopurifier ® as Part of a Machine Perfusion Circ...
Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025
Aethlon Medical invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO , Feb. 1...
Aethlon Medical, Inc. (AEMD) Q3 2025 Earnings Call Transcript
Aethlon Medical, Inc. (NASDAQ:AEMD) Q3 2025 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Jim Frakes – Chief Executive Officer Steven LaRosa – Chief Medical Officer Confe...
Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update
Key Milestone Achieved: First Patient treated in Hemopurifier® Safety, Feasibility, and Dose Finding Study for Solid Tumors Not Responding to Anti-PD-1 Antibodies Patient Enrollment Open at Two Austra...
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025
SAN DIEGO , Feb. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, to...
Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial
First Patient enrolled and treated at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DI...
Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu
SAN DIEGO , Dec. 20, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, t...
Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 14, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases a snapshot...
Aethlon Medical, Inc. (AEMD) Q2 2025 Earnings Call Transcript
Aethlon Medical, Inc. (NASDAQ:AEMD) Q2 2025Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relations, Rx Communications James Frakes - Interim Chi...
Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update
Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Ant...
Innovative Medical Technology Advances with First Patient Enrollments
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 12, 2024) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future of medical te...
Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia
Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors N...
Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024
SAN DIEGO , Nov. 6, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, to...
Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit
SAN DIEGO , Oct. 8, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, t...
Immunotherapy Clinical Trials - A New Approach to Treating Cancer
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - September 19, 2024) - Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and dev...
Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India
Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumors...
Aethlon Medical to Present at Virtual Investor Conferences in September
SAN DIEGO , Sept. 17, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases,...
Innovation Driving Cancer's Solid Tumors Market
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - September 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at news and deve...
Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial
Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Sept. 16, 2024 /PRNewswire/ -- Ae...
Aethlon Medical to Present at the Life Sciences Investor Forum September 19th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...
Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys
Results Support Future Study of the Hemopurifier® as Part of a Machine Perfusion Circuit to Further Assess its Association with Function of Retrieved Kidneys SAN DIEGO , Aug. 27, 2024 /PRNewswire/ -- ...
Aethlon Medical, Inc. (AEMD) Q1 2025 Earnings Call Transcript
Aethlon Medical, Inc. (NASDAQ:AEMD) Q1 2025 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relations, Rx Communications James Frakes - Interim Chie...